DSIP

Areas of active research — not promised effects

Each tag links to other compounds with research into that goal. Research use only: these are areas of study, not human-use claims.

Related by research scope · open each to compare

DSIP (emideltide) has no FDA-approved indication and cannot currently be prescribed or compounded under Section 503A. It was listed on the FDA Category-2 bulk drug substances list under the 2019 FDA-19 administrative action. The April 15, 2026 FDA update removed emideltide from Category 2 and referred it to the Pharmacy Compounding Advisory Committee (PCAC) for evaluation on July 24, 2026 (docket FDA-2025-N-6895). Until the PCAC evaluation is complete and a positive recommendation acted upon, DSIP remains restricted to research use only.

Transparent blend · bci-1.0 · never paid-placement

Primary name

DSIP

Origin

DSIP (Delta Sleep-Inducing Peptide, also known as emideltide) is an amphiphilic nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first isolated from rabbit thalamus perfusate in 1974 by Monnier and colleagues. It is found endogenously in both free and conjugated forms in the hypothalamus, limbic system, pituitary, and a variety of peripheral tissues and body fluids in mammals.

Registry IDs

PubChem CID

68816

CAS

62568-57-4

InChIKey

ZRZROXNBKJAOKB-GFVHOAGBSA-N

ChEMBL

CHEMBL2104403

Molecular formula

C35H48N10O15

Molar mass

848.8 g/mol

Monoisotopic

848.33006086 Da

InChIKey

ZRZROXNBKJAOKB-GFVHOAGBSA-N

Appearance

White to off-white lyophilized powder

Solubility

Soluble in water and aqueous buffers; limited solubility in organic solvents

Sequence not available in current seed.

Stability: Rapidly degraded by plasma aminopeptidases in vivo (t½ ~15 min). Lyophilized form is stable under recommended cold-chain conditions. In vitro degradation accele

Vial sizes

2 mg · 5 mg

Purity grades

>98% HPLC

Salt forms

Free base (primary)

• GHS hazard class on file
• PPE & spill response
• Disposal guidance
• Not-for-human-consumption posture

How much research exists, and of what maturity — never a verdict on whether it works.

Mechanism of action

• The precise mechanism of DSIP has not been fully established; no dedicated receptor gene has been cloned
• Evidence from preclinical work suggests interactions with NMDA receptors and alpha-1 adrenergic receptors, along with modulation of GABAergic tone, serotonin, noradrenaline, and histamine systems
• At the endocrine level, animal studies indicate suppression of basal corticotropin (ACTH) secretion and stimulatory effects on somatotropin and luteinizing hormone, with inhibition of somatostatin
• These pleiotropic actions are thought to collectively shift CNS activity toward slow-wave sleep states rather than acting as a direct sedative

Pharmacokinetics (ADME)

Half-life

~15 min (in vivo; rapid aminopeptidase-mediated N-terminal cleavage)

Clearance

Mean metabolic clearance rate ~30.7 ± 2.5 ml/kg (dog, immunoassay study; PMID 6379493)

PK–PD note: Extremely short plasma half-life limits bioavailability after systemic administration; BBB penetration has been demonstrated in rodent models, though the extent in humans is unknown.…

Reading the evidence

• Evidence quality and gaps vary by application — see the cited grades above.
• Indexed-article counts span all evidence tiers, not only completed human trials.
• No first-party human-dosing, efficacy, or benefit claims are made here.

No registered human trials found for this compound.

Status

No registered trials found

Summary (literature)

Published small human studies (predominantly open-label, 1980s) reported DSIP as generally well-tolerated; noted adverse effects included transient headache, nausea, vertigo, mild drowsiness, injection-site reactions, and episodic hypotension ranging from mild to moderate severit…

WADA status

Not specifically listed on the WADA Prohibited List. However, unapproved peptides may fall under the catch-all provision for non-approved pharmacological substa…

Dominant research route: Intravenous

Human RCTs (chronic insomniac patients, double-blind) and human pharmacokinetic characterization; also used in early rabbit/rat sleep induction studies

Bioavailability: IV administration delivers 100% systemic exposure; DSIP half-life in human plasma is ~7-8 min, with rapid degradation by aminopeptidases in blood

IV is the dominant route in published human sleep studies (e.g., 25 nmol/kg). The Bes et al. 1992 double-blind RCT in 16 chronic insomniac patients used IV infusion. Rapid plasma clearance limits duration of effect.

Human observational report (P300 ERP increase) and animal stroke recovery model (Sprague-Dawley rats, 8-day course)

Bioavailability: Intranasal route is proposed to bypass first-pass hepatic metabolism and plasma aminopeptidase degradation; no human PK/bioavailability value is published

Hruz et al. 2001 (J Clin Psychopharmacol, letter) reported intranasal DSIP increased P300 amplitude in humans. In an MDPI Molecules 2021 rat focal stroke study, intranasal DSIP over 8 days accelerated motor function recovery. No controlled human PK trial located.

No primary PK study located; described in aggregator/community literature as a common peptide injection route with lower bioavailability than IV

Bioavailability: Aggregator sources state SC has lower bioavailability than IV; no quantitative SC bioavailability figure sourced from a primary study

Subcutaneous use is referenced in community/aggregator peptide guides but no peer-reviewed SC pharmacokinetic or efficacy study for DSIP was retrieved. Treated as community route only.

Animal (mice) antinociceptive studies via central administration; original rabbit discovery used mesodiencephalic ventricular infusion

Bioavailability: Central (ventricular/cisternal) administration bypasses blood-brain barrier; not a peripheral bioavailability route

DSIP was originally isolated (1974) from rabbit cerebral venous blood and shown to induce sleep when infused into the mesodiencephalic ventricle of recipient rabbits. In mice, ICV/intracisternal DSIP produced potent antinociceptive effects. These are mechanistic/animal CNS-route studies, not standard parenteral routes.

Animal & human figures are kept visibly separate so studied animal doses are never misread as human guidance.

Sorted A–Z by vendor — never by price

Weekly median $/mg from the live vendor crawl.

Researched storefront prices, bucketed

p25 $6.00 · median $8.10 · p75 $8.80 · 9 researched vendors

Legit, COA-backed band: $4.50–$12.47/mg.

Value rule: don't just buy the cheapest — a price under $3/mg is a red flag. Pair price with COA and independent-test grade.

Estimated cost of research (10 mg)

Vial (best researched price)

$45

Bacteriostatic water (generic estimate)

$6

Syringes / supplies (generic estimate)

$12

What each test proves — general guidance, plus this compound's researched purity data

Independent labs cited for this compound

No DSIP-specific recalls, enforcement actions, or counterfeit alerts were found in FDA, WADA, or independent lab databases as of retrieval. DSIP is a research neuropeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Glu, ~850 Da) with no approved drug product, so no recall registry entry exists.

Buyer red-flag checklist

• No FDA-approved DSIP drug product exists; any marketed DSIP is sold as a research chemical and is not GMP-manufactured for human use.
• DSIP has low in vitro molecular stability (half-life ~15 minutes due to aminopeptidase-like degradation), raising risk of potency loss in non-cold-chain handling.
• No compound-specific import alert, warning letter, or recall was located — absence of enforcement does not equal verified quality.
• No independent third-party purity test results (Janoshik/MZ Biolabs/Finnrick) for DSIP were publicly retrievable at time of research.

GMP vs research-grade: the chemistry (SPPS + HPLC + MS) is identical — the difference is the quality system.

• An RUO label is not an import exemption — CBP judges actual intended use.
• Lyophilized powder is ambient-stable in transit; temperature control needed for > 7-day transit.
• US-warehouse vendors dodge import scrutiny — they cost more but ship more reliably.

Every item dated & sourced

DSIP is not explicitly named on the WADA 2026 Prohibited List but falls under the S0 (Non-Approved Substances) catch-all, which prohibits at all times any pharmacological substance with no current approval by any governmental regulatory health authority for human therapeutic use. S0 substances are classified as Specified, meaning a positive test carries a reduced default sanction (potentially two years rather than four) if the athlete proves no significant fault.

No granted patents identified in current seed. Composition-of-matter coverage is limited given the peptide's synthetic origin.

• IACUC / IRB research context
• RUO buyer responsibilities & documentation
• Veterinary / alternative-use where lawful
• Jurisdiction-aware "who may lawfully obtain"

What people discuss

Reported concerns — discussion, not established effects

Reading caveats

• insufficientRetrievableCommunityData
• searchAccessBlocked

Relative research / market volume — populated once the activity stream is wired

Inline tooltips for lyophilized, RUO, EU/mg, SPPS, 503A and more.

Toggle plain-language ↔ scientific in the header.

• How to read a COA
• Free base vs acetate
• Understanding evidence grades

Nine-amino-acid neuropeptide originally isolated from rabbit thalamus; studied in animals and small human trials for sleep regulation and opioid withdrawal. Approximately 351 articles are indexed (literature last scanned 2026-05-29). US regulatory status: Research Use Only — not approved, not currently compoundable; PCAC review pending. Research use only.

Emitted as JSON-LD: ChemicalSubstance · BreadcrumbList · FAQPage.

• Price-drop & back-in-stock alerts
• Regulatory-change email digest
• Print / share this datasheet